Eli Lilly and Company has issued a warning about potential safety risks linked to compounded tirzepatide mixed with vitamin B12. This combination, often marketed to consumers, has been found to contain harmful impurities resulting from a chemical reaction between tirzepatide and B12. The implications of these impurities are concerning, as their effects on human health remain unknown. People using these compounded products may be at risk, as they are not subject to the same rigorous testing and monitoring required for FDA-approved medications.

For those seeking to age well and maintain their health, this news highlights the importance of being cautious about the medications and supplements they choose. Tirzepatide is used for weight management and improving metabolic health, but when mixed with untested additives like B12, the safety and efficacy of the drug can be compromised. The risks associated with these compounded products could impact your overall health, especially if you are relying on them for weight loss or metabolic support.

The findings come from Eli Lilly’s testing of these compounded products, which revealed significant safety concerns. The research is early-stage and indicates a need for further investigation into the interactions between tirzepatide and additives like B12. While the FDA has begun taking action against the illegal compounding of these drugs, it is crucial for consumers to be aware of the potential dangers and to consult with healthcare professionals before using these products.

If you are considering tirzepatide or any compounded medications, it is essential to discuss your options with your doctor. They can provide guidance on safe and effective treatments, ensuring that you avoid potentially harmful products that lack proper testing and regulation.

Source: investor.lilly.com